Document is current
Any future updates will be listed below
-
Authors
Reguiai, Ziad https://orcid.org/0000-0003-4844-3559
Ghislain, Pierre-Dominique
Moulin, Pierre
Baudier, Emilie
Schepkens, Corentin
Sintès, Maxime
Boyé, Thierry
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04765332 at ClinicalTrials.govDocuments that mention this clinical trial
PSO-TARGET: a New Tool to Identify the Therapeutic Expectations of Psoriasis Patients Treated with Biologics
https://doi.org/10.1007/s13555-025-01356-8
-
Funding
Funding for this research was provided by:
LEO Pharma
- License Information
-
More Information
Article History
Received: 31 December 2024
Accepted: 31 January 2025
First Online: 21 February 2025
Declarations
:
: Prof Dr Pierre-Dominique Ghislain: speaker and hospital investigator for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Flen, Galderma, Janssen, LEO Pharma, Maruho, Meda, Menarini, MSD, Novartis, PellePharm, Pfizer, Serono, UCB et Viatris. Dr Thierry Boyé: Personal fees and grant (clinical research) Novartis, LEO Pharma, Janssen, Abbvie, Amgen, Lilly, UCB. Dr Ziad Reguiai: Abbvie, Almirall, Amgen, Celltrion, Boerhinger-Ingelheim, Bristol-Meyers-Squibb, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, Medac, MSD, Novartis, Pfizer, UCB. Prof Pierre Moulin: No conflict of interest. Emilie Baudier: Employee of LEO Pharma, Belgium. Corentin Schepkens: Corentin Schepkens who was affiliated to LEO Pharma NV/SA, Lier, Belgium at the time of study and publication is now affiliated to MSD, Belgium. He worked for LEO Pharma, Belgium during the statistical analysis and the drafting of the manuscript. Maxime Sintès: Employee of LEO Pharma, France.
: The study protocol was approved by the Ethics Committee OUEST III on 13th of May 2020 in France, and the Ethics Committees of UC Louvain on 3rd of February 2021 in Belgium. All patients included in the study provided their signed, informed consent to participate.
